Strata Critical Medical (SRTA)


Market Price (11/19/2026): $4.95 | Market Cap: $442.1 MilSector: Health Care | Industry: Health Care Facilities

Strata Critical Medical (SRTA)


Market Price (11/19/2026): $4.95
Market Cap: $442.1 Mil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 68%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Remote Patient Monitoring, Health Data Analytics, and AI in Healthcare Management.

Weak multi-year price returns
2Y Excs Rtn is -10%, 3Y Excs Rtn is -55%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -19 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.6%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 41x

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 68%
1 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Remote Patient Monitoring, Health Data Analytics, and AI in Healthcare Management.
2 Weak multi-year price returns
2Y Excs Rtn is -10%, 3Y Excs Rtn is -55%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -19 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.6%
4 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 41x
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%

SRTA in ETFs

Weight = SRTA's share of each fund

VTI0.00%
IWM0.01%
IWN0.03%
DFAS0.01%
VTWO0.01%
DFAC0.00%
IWV0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 18: down 5.3% in one day (S&P 500 down 0.3%)
The stock declined without company-specific news. It occurred on a day when the broader market also fell.

Up 41.4% from its Oct 14 low to Nov 9, down 18.0% since (S&P 500 down 2.2%)
The stock's run was primarily driven by its third quarter 2026 earnings report, which showed significant revenue growth. The company rose sharply on November 4, following its strong revenue results, and again on November 9 amid a broad market relief rally.

Nov 4: up 17.6% the day after its Nov 3 earnings report (S&P 500 up 1.7%)
The stock surged after Strata Critical Medical reported third quarter 2026 revenue increased 50.3% year-over-year to $74.1 million. This strong revenue growth overshadowed its net loss from continuing operations, occurring on a positive market day.

Show more
Prices as of 11/18/2026

Nov 18: down 5.3% in one day (S&P 500 down 0.3%)
The stock declined without company-specific news. It occurred on a day when the broader market also fell.

Up 41.4% from its Oct 14 low to Nov 9, down 18.0% since (S&P 500 down 2.2%)
The stock's run was primarily driven by its third quarter 2026 earnings report, which showed significant revenue growth. The company rose sharply on November 4, following its strong revenue results, and again on November 9 amid a broad market relief rally.

Nov 4: up 17.6% the day after its Nov 3 earnings report (S&P 500 up 1.7%)
The stock surged after Strata Critical Medical reported third quarter 2026 revenue increased 50.3% year-over-year to $74.1 million. This strong revenue growth overshadowed its net loss from continuing operations, occurring on a positive market day.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -1.2% change in SRTA stock from 7/31/2026 to 11/18/2026 was primarily driven by a -16.8% change in the company's P/S Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)5.024.96-1.2%
Change Contribution By: 
Total Revenues ($ Mil)22928122.8%
P/S Multiple1.91.6-16.8%
Shares Outstanding (Mil)8588-3.3%
Cumulative Contribution-1.2%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
SRTA-1.2% 
Market (SPY)-2.0%45.7%
Sector (XLV)11.9%38.5%

Fundamental Drivers

The -1.2% change in SRTA stock from 4/30/2026 to 11/18/2026 was primarily driven by a -27.7% change in the company's P/S Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)5.024.96-1.2%
Change Contribution By: 
Total Revenues ($ Mil)19728142.4%
P/S Multiple2.21.6-27.7%
Shares Outstanding (Mil)8588-4.1%
Cumulative Contribution-1.2%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
SRTA-1.2% 
Market (SPY)2.1%52.2%
Sector (XLV)25.1%16.1%

Fundamental Drivers

The -1.4% change in SRTA stock from 10/31/2025 to 11/18/2026 was primarily driven by a -41.5% change in the company's P/S Multiple.
(LTM values as of)1031202511182026Change
Stock Price ($)5.034.96-1.4%
Change Contribution By: 
Total Revenues ($ Mil)15428182.9%
P/S Multiple2.71.6-41.5%
Shares Outstanding (Mil)8188-7.9%
Cumulative Contribution-1.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
SRTA-1.4% 
Market (SPY)8.2%48.1%
Sector (XLV)27.7%17.0%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
SRTA  
Market (SPY)81.1%45.3%
Sector (XLV)52.9%17.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
SRTA Return----10%3%14%
Peers Return8%33%2%-4%37%50%192%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
SRTA Win Rate----40%45% 
Peers Win Rate47%50%44%50%50%60% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
SRTA Max Drawdown------34% 
Peers Max Drawdown-49%-61%-64%-53%-34%-40% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMDX, CYRX, BLFS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

SRTA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to TMDX, CYRX, BLFS

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

SRTA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to TMDX, CYRX, BLFS

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Strata Critical Medical (SRTA)

Blade Air Mobility, Inc., trading under the symbol SRTA, provides premium air transportation services designed to offer efficient alternatives to congested ground routes within the United States. The company's core business revolves around minimizing travel time and improving convenience for passengers by leveraging airborne solutions.

The company's main products and services include both charter flights and by-the-seat bookings. These services utilize a diverse fleet of aircraft, including helicopters, jets, turboprops, and amphibious seaplanes, allowing for flexible travel solutions tailored to various distances and passenger needs.

Blade Air Mobility primarily serves customers within the United States who are looking for rapid and direct travel options, particularly in areas where ground transportation is time-consuming. Its market consists of individuals and businesses seeking faster, more convenient, and often point-to-point travel experiences compared to traditional commuting methods.

AI Analysis | Feedback

  • Uber/Lyft for urban and regional air transportation via helicopters and seaplanes.
  • Like NetJets, but for by-the-seat bookings on helicopters and small aircraft for quick, short-distance routes.

AI Analysis | Feedback

  • Charter Flights: Private air transportation services for individuals or groups using helicopters, jets, turboprops, and amphibious seaplanes.
  • By-the-Seat Flights: Scheduled air transportation services where passengers can book individual seats on helicopters, jets, turboprops, and amphibious seaplanes.

AI Analysis | Feedback

null

AI Analysis | Feedback

  • Helijet Charters Inc.

AI Analysis | Feedback

Melissa M. Tomkiel, Co-Chief Executive Officer and General Counsel

  • Melissa Tomkiel is the Co-CEO and General Counsel of Strata Critical Medical, Inc.. She also serves on Strata's board of directors.
  • Before her current role, she served as President and General Counsel of Blade Air Mobility, the predecessor company to Strata, which she joined in 2015.
  • Prior to Blade, Ms. Tomkiel co-founded and was President of Fly The Whale, a commuter air carrier operating amphibious seaplanes and rotorcraft. She began her career as an attorney at Pryor Cashman.
  • Ms. Tomkiel was appointed Co-CEO when Blade Air Mobility rebranded to Strata Critical Medical in August 2025. She has made significant stock purchases in Strata (SRTA).

William A. Heyburn, Co-Chief Executive Officer and Chief Financial Officer

  • William Heyburn is the Co-CEO and Chief Financial Officer of Strata Critical Medical, Inc., and also serves as a director.
  • He previously held the positions of Chief Financial Officer and Head of Corporate Development at Blade Air Mobility, which he joined in 2018.
  • Before joining Blade Air Mobility, Mr. Heyburn was a Vice President at RedBird Capital Partners, a principal investment firm specializing in growth equity, build-up, and structured equity investments.
  • He was appointed Co-CEO and CFO in August 2025, concurrent with the company's rebranding. He purchased 17,000 shares of Strata Critical Medical Inc on December 9, 2025.

Scott M. Wunsch, Chief Executive Officer, Logistics

  • Scott Wunsch is the CEO of Strata's Logistics business.
  • He joined Trinity Medical Solutions in 2018, a company later acquired by Strata in 2021.
  • Prior to Trinity, Mr. Wunsch spent 13 years at LifeCenter Northwest, where he was the Vice President of Clinical Operations, managing overall operations and logistics for one of the largest geographic organ procurement organizations in the country.

Amir M. Cohen, Chief Accounting & Integration Officer

  • Amir Cohen is Strata's Chief Accounting & Integration Officer.
  • He played a key role in building the company's accounting organization through its transition from private to public and led significant aspects of the passenger-business carve-out.
  • Before joining Strata, Mr. Cohen held senior finance roles at various WPP agencies and WPP's global headquarters, and previously worked as a manager at PwC. He holds an MBA from NYU Stern and is a CPA.

Mathew Schneider, Vice President of Finance and Investor Relations, and CFO of Clinical Services

  • Mathew Schneider has served as Strata's Vice President of Finance and Investor Relations since April 2024 and as Chief Financial Officer of Strata's Clinical Services business since October 2025.
  • Prior to Strata, he worked as a senior analyst at Holocene Advisors L.P. and an analyst at Glenhill Capital L.P., focusing on the Industrial sector.
  • Mr. Schneider also served as a Vice President in Morgan Stanley's equity research division and an Associate in UBS's equity research division.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Strata Critical Medical (symbol: SRTA) focuses on time-critical logistics and specialized medical services for the U.S. healthcare industry. The company, which was formerly known as Blade Air Mobility, Inc., rebranded to Strata Critical Medical, Inc. in August 2025 after selling its passenger division.

Strata Critical Medical's main products and services include air and ground transportation for human organs, transplant teams, and related medical materials, as well as organ placement services. It also provides transplant clinical services such as organ recovery procedures, normothermic regional perfusion, and preservation services. Additionally, the company offers cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals.

The company plays a significant role in the U.S. organ transport market, dominating approximately 90% of this sector.

The addressable markets for Strata Critical Medical's main products and services are primarily within the United States:

  • Organ Transport Service Market (U.S.): The global organ transport service market is projected to grow from USD 4.40 billion in 2025 to USD 4.74 billion in 2026, and further to USD 9.40 billion by 2035. North America accounts for approximately 41% of this global market. The U.S. organ transport service market is anticipated to experience substantial growth due to increasing organ transplant procedures and advancements in medical technologies.
  • U.S. Transplantation Market: The U.S. transplantation market size was valued at USD 3.40 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 9.1% during the forecast period.
  • Organ Preservation Market (U.S.): The global organ preservation market size was USD 280.7 million in 2024 and is expected to reach USD 510.0 million by 2032, growing at a CAGR of 7.9% during 2025–2032. The U.S. performed 48,149 transplants in 2024, indicating a high demand for organ preservation solutions.

Strata Critical Medical's projected revenues were between $160 million and $170 million for 2025, and the company has raised its 2026 revenue guidance to between $260 million and $275 million.

AI Analysis | Feedback

null

AI Analysis | Feedback

The company Strata Critical Medical, Inc. (SRTA) provides time-critical logistics and medical services to the healthcare industry in the United States. It was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025, at which point its ticker changed from BLDE to SRTA. The company focuses on services such as air and ground transportation for human organs, transplant teams, and related medical materials. Here is a summary of Strata Critical Medical's capital allocation decisions over the last 3-5 years, reflecting its operations as Blade Air Mobility's medical division and subsequently as Strata Critical Medical:

Capital Allocation Decisions

  • Share Issuance
    • Strata Critical Medical had 86.4 million shares outstanding as of February 23, 2026.
    • As of March 14, 2026, the company had 86.99 million shares outstanding.
  • Inbound Investments
    • Strata announced the closing of a revolving credit facility in February 2026 to support its acquisition strategy execution.
  • Outbound Investments
    • Strata Critical Medical aims to strategically expand its portfolio of services through acquisition and organic growth.

Better Bets vs. Strata Critical Medical (SRTA)

Peer Outperformance in Health Care Facilities

null
Share of Health Care Facilities constituents that SRTA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
50%
of 30 industry peers · 12.5% return
3Y
—
insufficient peer history
5Y
—
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Facilities is SRTA's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities ← 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

SRTATMDXCYRXBLFSMedian
NameStrata C.TransMed.CryoPort BioLife . 
Mkt Price4.9596.5020.17-20.17
Mkt Cap0.43.31.01.91.5
Rev LTM281728192103237
Op Inc LTM-1986-383-8
FCF LTM-045-20-2-1
FCF 3Y Avg-3215-302-14
CFO LTM11112111714
CFO 3Y Avg-14109-4113

Growth & Margins

SRTATMDXCYRXBLFSMedian
NameStrata C.TransMed.CryoPort BioLife . 
Rev Chg LTM68.4%28.5%11.8%25.4%26.9%
Rev Chg 3Y Avg14.9%59.6%5.6%23.0%18.9%
Rev Chg Q50.3%41.1%13.5%21.5%31.3%
QoQ Delta Rev Chg LTM9.7%8.9%3.2%5.1%7.0%
Op Inc Chg LTM14.8%-9.9%2.6%118.1%8.7%
Op Inc Chg 3Y Avg19.0%125.9%11.5%-25.3%15.3%
Op Mgn LTM-6.6%11.9%-20.0%2.9%-1.9%
Op Mgn 3Y Avg-17.2%12.2%-30.0%-8.9%-13.1%
QoQ Delta Op Mgn LTM1.3%-0.3%1.2%18.1%1.3%
CFO/Rev LTM3.8%15.4%5.7%16.4%10.6%
CFO/Rev 3Y Avg-8.9%18.7%-3.6%11.7%4.1%
FCF/Rev LTM-0.1%6.1%-10.3%-2.2%-1.2%
FCF/Rev 3Y Avg-17.6%-0.9%-21.4%1.2%-9.2%

Valuation

SRTATMDXCYRXBLFSMedian
NameStrata C.TransMed.CryoPort BioLife . 
Mkt Cap0.43.31.01.91.5
P/S1.64.65.318.45.0
P/Op Inc-23.538.7-26.5632.97.6
P/EBIT-23.533.9-30.9632.95.2
P/E-17.623.2-24.732.52.8
P/CFO40.729.892.9111.866.8
Total Yield-5.7%4.3%-4.0%3.1%-0.5%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-0.8%-6.2%0.2%0.2%
D/E0.00.30.20.00.1
Net D/E-0.10.1-0.2-0.0-0.1

Returns

SRTATMDXCYRXBLFSMedian
NameStrata C.TransMed.CryoPort BioLife . 
1M Rtn9.0%34.8%18.8%-18.8%
3M Rtn-16.0%2.7%23.7%5.9%4.3%
6M Rtn-10.6%41.9%43.4%60.9%42.6%
12M Rtn12.2%-17.6%140.4%60.7%36.5%
3Y Rtn13.3%40.5%48.1%202.3%44.3%
1M Excs Rtn9.4%32.9%19.5%-19.5%
3M Excs Rtn-14.0%9.2%23.6%7.4%8.3%
6M Excs Rtn-10.4%42.1%43.6%61.1%42.9%
12M Excs Rtn0.1%-26.1%125.9%49.7%24.9%
3Y Excs Rtn-54.7%-6.4%11.2%190.0%2.4%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Logistics177147   
Clinical200   
Medical  12772 
Passenger  9974 
MediMobility Organ Transport and Jet    26
Other    2
Short Distance    22
Total19714722514651


Operating Income by Segment
$ Mil202420232022
Medical1911-3
Passenger4-5-14
Gain on lease modification1  
Executive severance costs-0-0 
M&A transaction costs-0  
SOX readiness costs-0-0 
Restructuring costs-1  
Legal and regulatory advocacy fees-2-1 
Impairment of intangible assets-6-21 
Depreciation and amortization-6-7 
Stock-based compensation-20-13 
Adjusted unallocated corporate expenses and software development-22-22-37
Contingent consideration compensation (earn-out) -10 
Total-34-68-54


Price Behavior

Price Behavior
Market Price$4.96 
Market Cap ($ Bil)0.4 
First Trading Date09/13/2019 
Distance from 52W High-23.3% 
   50 Days200 Days
DMA Price$5.01$5.10
DMA Trenddowndown
Distance from DMA-1.1%-2.8%
 3M1YR
Volatility59.2%56.8%
Downside Capture270.86228.16
Upside Capture266.65224.79
Correlation (S&P 500)43.8%46.5%
SRTA Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.431.541.992.212.080.19
Up Beta3.071.691.852.061.860.19
Down Beta1.241.581.461.931.970.38
Up Capture27%70%195%258%310%34%
Bmk +ve Days12182862130427
Stock +ve Days9172856115135
Down Capture220%228%234%207%161%94%
Bmk -ve Days10253664121325
Stock -ve Days12253367132154

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SRTA
SRTA11.5%56.8%0.39-
Sector ETF (XLV)21.5%17.0%0.9616.2%
Equity (SPY)10.9%13.8%0.4946.5%
Gold (GLD)-8.2%29.0%-0.3035.5%
Commodities (DBC)28.8%21.5%1.07-13.3%
Real Estate (VNQ)11.2%14.2%0.5022.2%
Bitcoin (BTCUSD)-29.6%43.7%-0.6938.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SRTA
SRTA2.6%59.4%0.39-
Sector ETF (XLV)8.0%15.4%0.3317.2%
Equity (SPY)11.0%17.3%0.4645.3%
Gold (GLD)14.5%19.2%0.6032.0%
Commodities (DBC)6.8%19.6%0.24-9.9%
Real Estate (VNQ)1.1%19.0%-0.0521.8%
Bitcoin (BTCUSD)-0.0%51.4%0.1835.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SRTA
SRTA1.3%59.4%0.39-
Sector ETF (XLV)12.1%16.8%0.5917.2%
Equity (SPY)14.9%18.0%0.7045.3%
Gold (GLD)10.9%16.6%0.5332.0%
Commodities (DBC)7.2%18.2%0.31-9.9%
Real Estate (VNQ)5.8%20.7%0.2421.8%
Bitcoin (BTCUSD)57.1%66.3%0.9735.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity4.6 Mil
Short Interest: % Change Since 101520260.3%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest5.0 days
Basic Shares Quantity88.3 Mil
Short % of Basic Shares5.2%

Earnings Returns History

Updated 11/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/20263.7%41.4% 
8/4/20260.4%7.0%-3.2%
5/6/202610.6%13.5%29.9%
3/3/20266.9%1.8%-6.9%
11/10/20259.5%8.1%4.3%
SUMMARY STATS   
# Positive552
# Negative002
Median Positive6.9%8.1%17.1%
Median Negative  -5.1%
Max Positive10.6%41.4%29.9%
Max Negative  -6.9%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/20263.7%41.4% 
8/4/20260.4%7.0%-3.2%
5/6/202610.6%13.5%29.9%
3/3/20266.9%1.8%-6.9%
11/10/20259.5%8.1%4.3%
SUMMARY STATS   
# Positive552
# Negative002
Median Positive6.9%8.1%17.1%
Median Negative  -5.1%
Max Positive10.6%41.4%29.9%
Max Negative  -6.9%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202608/04/202610-Q
03/31/202605/06/202610-Q
12/31/202503/03/202610-K
09/30/202511/10/202510-Q
06/30/202508/05/202510-Q
03/31/202505/12/202510-Q
12/31/202403/13/202510-K
09/30/202411/12/202410-Q
06/30/202408/08/202410-Q
03/31/202405/07/202410-Q
12/31/202303/12/202410-K
09/30/202311/08/202310-Q
06/30/202308/09/202310-Q
03/31/202305/11/202310-Q
12/31/202203/16/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202608/04/202610-Q
03/31/202605/06/202610-Q
12/31/202503/03/202610-K
09/30/202511/10/202510-Q
06/30/202508/05/202510-Q
03/31/202505/12/202510-Q
12/31/202403/13/202510-K
09/30/202411/12/202410-Q
06/30/202408/08/202410-Q
03/31/202405/07/202410-Q
12/31/202303/12/202410-K
09/30/202311/08/202310-Q
06/30/202308/09/202310-Q
03/31/202305/11/202310-Q
12/31/202203/16/202310-K
09/30/202211/10/202210-Q
06/30/202208/09/202210-Q
03/31/202205/10/202210-Q
12/31/202102/10/202210-QT
09/30/202112/20/202110-K
06/30/202108/16/202110-Q

Recent Forward Guidance

Updated 11/4/2026

Latest: Q3 2026 Earnings Reported 11/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported285.00 Mil290.00 Mil295.00 Mil0.0% AffirmedGuidance: 290.00 Mil for 2026
2026 Pro Forma RevenueReported295.00 Mil300.00 Mil305.00 Mil0.0% AffirmedGuidance: 300.00 Mil for 2026
2026 Adjusted EBITDAReported33.00 Mil34.00 Mil35.00 Mil0.0% AffirmedGuidance: 34.00 Mil for 2026
2026 Pro Forma Adjusted EBITDAReported36.00 Mil37.00 Mil38.00 Mil0.0% AffirmedGuidance: 37.00 Mil for 2026
2026 Free cash flow, before aircraft and engine acquisitionsReported15.00 Mil18.50 Mil22.00 Mil0.0% AffirmedGuidance: 18.50 Mil for 2026


Prior: Q1 2026 Earnings Reported 5/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported260.00 Mil267.50 Mil275.00 Mil0 AffirmedGuidance: 267.50 Mil for 2026
2026 Adjusted EBITDAReported29.00 Mil31.00 Mil33.00 Mil0 AffirmedGuidance: 31.00 Mil for 2026
2026 Free Cash FlowReported15.00 Mil18.50 Mil22.00 Mil0 AffirmedGuidance: 18.50 Mil for 2026

Q4 2025 Earnings Reported 3/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported260.00 Mil267.50 Mil275.00 Mil1.9% RaisedGuidance: 262.50 Mil for 2026
2026 Adjusted EBITDAReported29.00 Mil31.00 Mil33.00 Mil3.3% RaisedGuidance: 30.00 Mil for 2026
2026 Adjusted EBITDA Growth RateReported 30.0%    
2026 Free Cash FlowReported15.00 Mil18.50 Mil22.00 Mil   

Insider Activity

Updated 11/9/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Lauck, Andrew DirectBuy110920265.002,0009,998864,337Form
2Love, Reginald DirectSell81320265.755,09129,273842,266Form
3Heyburn, William ACo-CEO and CFODirectSell61020265.8731,671185,9099,092,612Form
4Cohen, AmirChief Accounting OfficerDirectSell61020265.874,65527,325860,589Form
5Tomkiel, Melissa MCo-CEO and General CounselDirectSell61020265.8729,730174,51511,110,583Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Lauck, Andrew DirectBuy110920265.002,0009,998864,337Form
2Love, Reginald DirectSell81320265.755,09129,273842,266Form
3Heyburn, William ACo-CEO and CFODirectSell61020265.8731,671185,9099,092,612Form
4Cohen, AmirChief Accounting OfficerDirectSell61020265.874,65527,325860,589Form
5Tomkiel, Melissa MCo-CEO and General CounselDirectSell61020265.8729,730174,51511,110,583Form
6Wunsch, Scott MCEO, LogisticsDirectSell61020265.875,55032,5783,672,119Form
7Cohen, AmirChief Accounting OfficerDirectSell52620265.9140,575239,798893,964Form
8Cohen, AmirChief Accounting OfficerDirectSell52620265.7910,30059,6371,110,742Form
9Cohen, AmirChief Accounting OfficerDirectSell51320265.7914,30682,8321,170,379Form
10Heyburn, William ACo-CEO and CFODirectBuy121020254.4717,00076,0446,277,850Form
11Lauck, Andrew DirectBuy120520254.375,00021,825592,077Form
12Love, Reginald DirectSell112420254.3711,00048,070497,730Form
13Love, Reginald DirectSell112020254.3111,00047,434538,581Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Northern Right Capital Management, L.P.$17.1 Mil6.1%25ADD +42.6%13F
Third Point LLC$20.9 Mil1.0%33Hold13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Northern Right Capital Management, L.P.$17.1 Mil6.1%25ADD +42.6%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Third Point LLC$20.9 Mil1.0%33Hold13F
Northern Right Capital Management, L.P.$17.1 Mil6.1%25ADD +42.6%13F
Core Cache Last Updated: 11/18/2026